Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quinapril hydrochloride, quantity: 5.416 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; povidone; calcium sulfate dihydrate; magnesium carbonate hydrate; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sumatriptan succinate, quantity: 140 mg (equivalent: sumatriptan, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; macrogol 8000; triacetin; polydextrose - iptam tablets are indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of iptam in the treatment of basilar or hemiplegic migraines.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sumatriptan succinate, quantity: 70 mg (equivalent: sumatriptan, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose monohydrate; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 8000; triacetin; iron oxide yellow; iron oxide red; polydextrose - iptam tablets are indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of iptam in the treatment of basilar or hemiplegic migraines.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 10 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; maize starch; iron oxide red; iron oxide yellow; sodium bicarbonate; lactose monohydrate; magnesium stearate - auspril tablets are indicated in the treatment of: hypertension: all grades of essential hypertension renovascular hypertension. congestive heart failure: all degrees of symptomatic heart failure. in such patients, it is recommended that auspril be administered together with a diuretic. left ventricular dysfunction: all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - enalapril maleate, quantity: 20 mg - tablet, uncoated - excipient ingredients: maize starch; pregelatinised maize starch; sodium bicarbonate; iron oxide red; lactose monohydrate; magnesium stearate - auspril tablets are indicated in the treatment of: hypertension: all grades of essential hypertension renovascular hypertension. congestive heart failure: all degrees of symptomatic heart failure. in such patients, it is recommended that auspril be administered together with a diuretic. left ventricular dysfunction: all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - aciclovir, quantity: 200 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - aciclovir tablets are indicated for use in adult patients for: (1) the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. (2) the treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. (3) the management of patients with advanced symptomatic hiv disease (cd4 + counts < 150 x 10(6)/l). in accordance with details specified in the "indications" and the "dosage and adminsitration" sections of the approved product information provided as attachment 1.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: glucose; propylene glycol; colloidal anhydrous silica; hyprolose; maize starch; povidone; hypromellose; magnesium stearate; titanium dioxide; purified talc - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and susceptibility tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; colloidal anhydrous silica; glucose; magnesium stearate; purified talc; povidone; titanium dioxide; maize starch; propylene glycol; hyprolose - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections in adults caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis, and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbation of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis. acute tonsillitis. impetigo. appropriate culture and susceptibility tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: silicon dioxide; titanium dioxide; hypromellose; lactose monohydrate; croscarmellose sodium; poloxamer; magnesium stearate; microcrystalline cellulose; povidone; macrogol 4000 - roxithromycin sandoz is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms. upper respiratory tract infection: acute pharyngitis, tonsilitis and sinusiti. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children roxithromycin sandoz 150mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible microorganisms. acute pharyngitis. acute tonsilitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be inititiated before results of these tests are known; once results become available, appropriate therapy should be continued.